Ovid Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Ovid Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- New York
- Headquarters state / province
- New York
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- OVID
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001636651
- EIN
- 46-5270895
Board of directors
-
Anna Greka · DirectorSince 2026
-
Barbara Gayle Duncan · DirectorSince 2023
-
Bart Friedman · DirectorSince 2023
-
Jeremy M. Levin · Director · Executive ChairmanSince 2023
-
Karen Bernstein · DirectorSince 2023
-
Kevin Joseph Fitzgerald · DirectorSince 2023
-
Margaret A. Alexander · Director · President and CEOSince 2026
-
Robert Michael Poole · DirectorSince 2023
-
Stelios Papadopoulos · DirectorSince 2025
Chief executives
Jeremy M. Levin
· CEO
Dates unknown
Margaret A. Alexander
· President and CEO
Dates unknown
Director election results
Annual meeting of July 10, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
75.6%
-
83.9%
Board connections
2 of this board's directors also sit on 3 other boards.
- via Barbara Gayle Duncan
- via Stelios Papadopoulos
- via Barbara Gayle Duncan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $29,286
- 2 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 6, 2026 | Carter Charles Ross Officer (Chief Financial Officer) | Grant or award | +50,000 | — | — |
| Apr 7, 2026 | Stelios Papadopoulos Director | Grant or award | +17,578 | $2.56 | $45,000 |
| Apr 7, 2026 | Bart Friedman Director | Grant or award | +8,789 | $2.56 | $22,500 |
| Apr 7, 2026 | Kevin Joseph Fitzgerald Director | Grant or award | +17,578 | $2.56 | $45,000 |
| Mar 23, 2026 | Jeremy M. Levin Director, Officer (Executive Chairman) | Option exercise | +47,333 | $1.40 | $66,266 |
| Feb 26, 2026 | Rona Jeffrey A Officer (CBFO) | Grant or award | +68,125 | — | — |
| Feb 23, 2026 | Rona Jeffrey A Officer (CBFO) | Open-market sale | −8,541 | $1.45 | $12,384 |
| Feb 23, 2026 | Margaret A. Alexander Director, Officer (President and CEO) | Open-market sale | −11,656 | $1.45 | $16,901 |
| Dec 15, 2025 | Jeremy M. Levin Director, Officer (CEO) | Derivative conversion | +71,000 | — | — |
| Dec 8, 2025 | Takeda Pharmaceuticals U.S.A., Inc. 10% owner | Derivative conversion | +1,250,000 | — | — |
| Feb 26, 2025 | ALEXANDER MARGARET A. Officer (President and COO) | Open-market sale | −5,279 | $0.56 | $2,956 |
| Feb 26, 2025 | Rona Jeffrey A Officer (CBFO) | Open-market sale | −3,902 | $0.56 | $2,185 |
| Feb 20, 2025 | Rona Jeffrey A Officer (CBFO) | Grant or award | +43,750 | — | — |
| Feb 20, 2025 | ALEXANDER MARGARET A. Officer (President and COO) | Grant or award | +43,750 | — | — |
| Jan 27, 2025 | ALEXANDER MARGARET A. Officer (President and COO) | Open-market purchase | +6,810 | $0.73 | $4,971 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.